MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412861 | Name: CI 959

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CI 959 is a novel antiallergic compound which is a potent inhibitor of receptor-mediated histamine release from human basophils. It inhibits thromboxanes.

Chemical Structure

CI 959
CI 959
CAS#104795-68-8

Theoretical Analysis

MedKoo Cat#: 412861

Name: CI 959

CAS#: 104795-68-8

Chemical Formula: C14H14N5NaO3S

Exact Mass: 355.0715

Molecular Weight: 355.35

Elemental Analysis: C, 47.32; H, 3.97; N, 19.71; Na, 6.47; O, 13.51; S, 9.02

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CI959; CI-159 CI 159
IUPAC/Chemical Name
Benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-, monosodium salt
InChi Key
UCLODRCAPZIYOW-UHFFFAOYSA-M
InChi Code
InChI=1S/C14H15N5O3S.Na/c1-7(2)22-11-9-6-8(21-3)4-5-10(9)23-12(11)13(20)15-14-16-18-19-17-14;/h4-7H,1-3H3,(H2,15,16,17,18,19,20);/q;+1/p-1
SMILES Code
O=C(C1=C(OC(C)C)C2=CC(OC)=CC=C2S1)[N-]C3=NN=NN3.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 355.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Koller LD, Voller BE, Hedstrom OR, Steppan LG, Kerkvliet NI, Thueson DO. Effect of CI-949 and CI-959 on immune function and lymphoid organs in rats. Int J Immunopharmacol. 1989;11(5):509-16. doi: 10.1016/0192-0561(89)90180-x. PMID: 2807627. 2: Wright CD, Stewart SF, Kuipers PJ, Hoffman MD, Devall LJ, Kennedy JA, Ferin MA, Thueson DO, Conroy MC. Selective regulation of human neutrophil functions by the cell activation inhibitor CI-959. J Leukoc Biol. 1994 Apr;55(4):443-51. doi: 10.1002/jlb.55.4.443. PMID: 8145014. 3: Bleavins MR, de la Iglesia FA, McCay JA, White KL Jr, Munson AE. Immunotoxicologic studies with CI-959, a novel benzothiophene cell activation inhibitor. Toxicology. 1995 Apr 12;98(1-3):111-23. doi: 10.1016/0300-483x(94)02985-4. PMID: 7740540. 4: Walsh KM, Courtney CL. Nasal toxicity of CI-959, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Toxicol Pathol. 1998 Nov-Dec;26(6):717-23. doi: 10.1177/019262339802600601. PMID: 9864087. 5: Low J, Grabow D, Sommers C, Wallace J, Lesch M, Finkel M, Schrier D, Metz A, Conroy MC. Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109(4):1224-33. doi: 10.1016/0016-5085(95)90582-0. PMID: 7557089. 6: Hach M, Christensen LB, Lange T, Hvidtfeldt UA, Danielsen B, Diderichsen F, Osler M, Prescott E, Andersen I. Social inequality in tooth loss, the mediating role of smoking and alcohol consumption. Community Dent Oral Epidemiol. 2019 Oct;47(5):416-423. doi: 10.1111/cdoe.12468. Epub 2019 May 20. PMID: 31111525. 7: Brinne Roos J, Bergenzaun P, Groth K, Lundell L, Arnelo U. Telepresence- teleguidance to facilitate training and quality assurance in ERCP: a health economic modeling approach. Endosc Int Open. 2020 Mar;8(3):E326-E337. doi: 10.1055/a-1068-9153. Epub 2020 Feb 21. PMID: 32118106; PMCID: PMC7035055. 8: Adolphson RL, Schellenberg RR, Thueson DO, Conroy MC. CI-959, a new, potential antiallergic drug, inhibits mediator release from lung and contractions of human airways in vitro. Int Arch Allergy Appl Immunol. 1990;93(2-3):267-71. doi: 10.1159/000235312. PMID: 1712004. 9: Low JE, Metz AL, Mertz TE, Henry SP, Knowlton P, Loewen G, Sommers CS, Robertson DG, Olszewski BJ, Schroeder RL, et al. Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound: morphologic features and pharmacokinetic and pharmacodynamic mechanisms. J Cardiovasc Pharmacol. 1995 Jun;25(6):930-9. doi: 10.1097/00005344-199506000-00011. PMID: 7564338. 10: Burke SE, Wright CD, Potoczak RE, Boucher DM, Dodd GD, Taylor DG Jr, Kaplan HR. Reduction of canine myocardial infarct size by CI-959, an inhibitor of inflammatory cell activation. J Cardiovasc Pharmacol. 1992 Oct;20(4):619-29. doi: 10.1097/00005344-199210000-00016. PMID: 1280719.